Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE SR versus KAINAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE SR versus KAINAIR.
AEROLATE SR vs KAINAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
25 mg subcutaneously three times daily.
None Documented
None Documented
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Category C
Category C
Bronchodilator
Bronchodilator